期刊文献+

短期胰岛素强化治疗初诊2型糖尿病对胰岛β细胞功能影响的观察 被引量:5

The Effects of Short-term Intensive Insulin Treatment on Pancretic β Cell Function in Newly Diagnosed Type 2 Diabetic Patients
原文传递
导出
摘要 目的 观察短期胰岛素强化治疗对伴明显高血糖的初诊 2型糖尿病患者的降糖效果和胰岛 β细胞功能的影响。 方法 对 2 7例空腹血糖 >13 1mmol/L的初诊T2 DM患者进行短期胰岛素强化治疗 ,分析比较其治疗前后空腹血糖 (FBS)、糖化血红蛋白(HbA1c)、空腹血胰岛素 (FINS)及餐后 2h血糖 (PBS2 )、胰岛 β细胞功能Homaβ及胰岛素敏感性指标HomaIR的变化。 结果 治疗 2周后 ,2 3例患者的空腹及餐后 2h血糖分别于治疗后 ( 5 6± 2 3 )d、( 8 5± 3 5 )d达到良好控制 ;FBS及PBS2 水平均较治疗前显著下降(P <0 0 1) ;HbA1c、HomaIR较治疗前下降 (P <0 0 5 )、Homaβ较治疗前增高 ( P <0 0 5 )。结论 对伴明显高血糖的初诊 2型糖尿病患者 ,短期胰岛素强化治疗具有快速控制血糖 ,从而明显改善 Objective To explore the effect of short-term intensive insulin treatment on pancreatic β-cell function and glycemia control in newly diagnosed type 2 diabetic patients with severe hyperglycemia. Methods Twenty-seven newly diagnosed type 2 diabetic patients with fasting blood sugar (FPG)>13.1mmol/L were treated by 2 weeks short-term intensive insulin treatment. FBS, Fasting blood insulin(FINS), glycosylated hemoglobin A1c (HbA1c), 2 hours postprandial blood sugar(PBS 2), Homa β and Homa IR were measured and compared between pre-treatment and post-treatment. Results After 2 weeks short-term intensive insulin treatment, the excellent control of FBS, PBS 2 in 23 out of 27 patients were achieved respectively in (5.6±2.3)days and (8.5±3.5)days. Homa β significantly increased, and HbA1c and Homa IR decreased comared with pre-treatment. Conclusions The excellent glycemia control and improvement of β-cell function can be induced by short-term intensive insulin treatment in newly diagnosed type 2 diabetic patients with severe hyperglycemia.
出处 《中国医师杂志》 CAS 2004年第1期82-83,共2页 Journal of Chinese Physician
关键词 胰岛素 2型糖尿病 胰岛Β细胞 血糖 强化治疗 Type 2 diabetes mellitus Insulin Therapeautics Pancreatic beta cells
  • 相关文献

参考文献5

  • 1刘国良.糖尿病诊断治疗的最新进展[J].中国实用内科杂志,2000,20(1):29-32. 被引量:159
  • 2杨文英.胰岛素治疗临床实践中的经验和教训[J].国外医学(内分泌学分册),2003,23(3):168-171. 被引量:145
  • 3Purrello F,Rabuazza AM. Metabolic factors that affect beta-cell function and survival[J].Diabet Nutr Metab ,2000,13:84-91
  • 4Sivitz WI .Lipotoxicity and glucotoxicity in type 2 diabetes. Ef-fects on development and progression[J].Postgrad Med,2001,109:55-59,63-64
  • 5Kahn SE.The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus[J].Am J Med, 2000, 108suppl 6a:2-8

二级参考文献1

共引文献302

同被引文献46

  • 1郭瑞金,薛元明,施珏,蔡玮.人胰岛素类似物(Insulin Aspart)持续皮下注射治疗2型糖尿病[J].中华内分泌代谢杂志,2005,21(3):278-279. 被引量:24
  • 2Uusitupa M I, Niskanen L K, Siitonen O, et al. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipo-protein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia, 1993, 36 (11): 1175-1184
  • 3Clark C M Jr. How should we respond to the worldwide diabetes epidemic. Diabetes Care, 1998, 21(4): 475-476
  • 4Aiello L P, Gardner T W, King G L, et al. Diabetic retinopathy. Diabetes Care, 1998, 21(1): 143-156
  • 5Mooradian A D. Drug therapy of non-insulin-dependent diabetes mellitus in the elderly. Drugs, 1996, 51(6): 931 -941
  • 6Scheen A J. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments. Drugs, 1997, 54(3): 355-368
  • 7Wente W, Efanov A M, Brenner M, et al. Fibroblast growth factor-21 improves pancreatic-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and akt signaling pathways. Diabetes, 2006, 55(9): 2470-2478
  • 8Kharitonenkov A, Wroblewski V J, Koester A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology, 2007, 148(2): 774-781
  • 9Kharitonenkov A, Shiyanova T L, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest, 2005, 115(6): 1627-1635
  • 10Marblestone J G, Edavettal S C, Lim Y, et al. Comparison of SUMO fusion technology with traditional gene fusion systems: Enhanced expression and solubility with SUMO. Protein Science,15(1): 182- 189

引证文献5

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部